HER-2 Positive Advanced Gastric Cancer
Conditions
Keywords
HM781-36B, Paclitaxel, Trastuzumab
Brief summary
\[Phase I\] The main objective of this study is to evaluate the safety, tolerability and determine the Recommended Dose (RD) of HM781-36B(Poziotinib)combined with Paclitaxel and Trastuzumab \[Phase II\] The main objective of this study is to evaluate anticancer activity through determination of response rate of HM781-36B(Poziotinib)combined with Paclitaxel and Trastuzumab in patients with HER-2 positive advanced gastric cancer
Detailed description
Besides the main objectives, there are other objectives as follows: \[Phase I\] 1. To assess the pharmacokinetic profile of HM781-36B(Poziotinib) combined with Paclitaxel and Trastuzumab 2. To evaluate anticancer activity of HM781-36B(Poziotinib) combined with Paclitaxel and Trastuzumab in patients with HER-2 positive advanced gastric cancer 3. To evaluate PFS(Progression-Free Survival), TTP (Time To Tumor Progression), and DOR (Duration of Overall Response) \[Phase II\] 1. To assess the safety, tolerability of HM781-36B(Poziotinib) combined with Paclitaxel and Trastuzumab 2. To evaluate tumor response through determination of disease control rate , PFS(Progression-Free Survival), TTP (Time To Tumor Progression), and DOR (Duration of Overall Response)
Interventions
DRUGHM781-36B(Poziotinib)
QD\*2weeks/3weeks
DRUGPaclitaxel
175mg/m2
DRUGTrastuzumab
8mg/kg
Sponsors
National OncoVenture
Hanmi Pharmaceutical Company Limited
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically or cytologically confirmed advanced gastric cancer including gastroesophageal junction adenocarcinoma 2. At least one measurable lesion defined by RECIST(v1.1) 3. FISH+ or IHC3+ (regardless of FISH results) 4. Age≥19 5. ECOG ≤ 2 6. Life expectancy ≥ 12 weeks 7. Adequate bone marrow and no abnormal heart and lung function 8. No radiotherapy, other anticancer drugs or immunotherapy is allowed during this study 9. Subjects must provide written informed consent prior to performance of study specific procedures or assessments, and must be willing to comply with treatment and follow up assessments and procedures
Exclusion criteria
1. Patients with a history of hypersensitivity to Trastuzumab and who have been treated with medicine including Cremophor EL 2. Patients who have a current active malignancy other than gastric adenocarcinoma (with exception of non-melanoma skin cancer or cervical cancer in situ) 3. Patients who have previously received taxane-based chemotherapy 4. The presence of central nervous system metastases 5. Patients who have a blood tumor such as leukemia, or who had previously received, or are planning to receive, the bone marrow transplant 6. Patients with uncontrolled infection 7. Patients who have GI malabsorption or difficulty taking oral medication 8. Patients with following diseases are excluded: 9. Patients with psychiatric or congenital disorder which can affect adherence or make hard to follow the requirements of the protocol 10. Pregnant or breastfeeding women or women of childbearing who do not use an appropriate method of contraception (male patient should also use an appropriate method of contraception)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety evaluation(phase I) | DLT will be evaluated on Day 21 during cycle 1 | Dose limiting toxicity (DLT), Maximum tolerance dose (MTD) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy evaluation(Phase II) | Efficacy will be evaluated every 6 weeks or 9 weeks | Efficacy evaluation; phase II (Simon's two-stage minimax design): Disease Control Rate (CR, PR, SD), PFS(Progression-Free Survival), TTP (Time To Tumor Progression), and DOR (Duration of Overall Response) |
Countries
South Korea
Outcome results
None listed